**Trader consensus heavily favors no new COVID variant of concern before 2027, with "No" priced at 86.5%.** This reflects the absence of any SARS-CoV-2 variants meeting WHO or ECDC VOC criteria as of mid-2026, despite ongoing genomic surveillance. Recent sublineages such as BA.3.2 (nicknamed Cicada), NB.1.8.1 (Nimbus), and XFG have circulated with notable spike mutations and some immune-escape potential, yet they remain classified only as variants under monitoring or of interest due to limited impact on severity, hospitalization, or overall public health risk. ECDC reports confirm no current VOCs, with earlier lineages de-escalated years ago. BA.3.2 detections rose modestly through late 2025 and early 2026 but stayed low in prevalence (under 1% in U.S. surveillance) and did not drive surges or policy changes. Vaccine updates for the 2025–26 and 2026–27 seasons target dominant circulating strains like XFG lineages, supporting expectations of continued incremental Omicron evolution rather than a disruptive new designation. With roughly 17 months until 2027, the market pricing aligns with the pattern of stable, low-consequence variant activity and robust monitoring systems.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日はい
$244,130 Vol.
$244,130 Vol.
はい
$244,130 Vol.
$244,130 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
マーケット開始日： Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...**Trader consensus heavily favors no new COVID variant of concern before 2027, with "No" priced at 86.5%.** This reflects the absence of any SARS-CoV-2 variants meeting WHO or ECDC VOC criteria as of mid-2026, despite ongoing genomic surveillance. Recent sublineages such as BA.3.2 (nicknamed Cicada), NB.1.8.1 (Nimbus), and XFG have circulated with notable spike mutations and some immune-escape potential, yet they remain classified only as variants under monitoring or of interest due to limited impact on severity, hospitalization, or overall public health risk. ECDC reports confirm no current VOCs, with earlier lineages de-escalated years ago. BA.3.2 detections rose modestly through late 2025 and early 2026 but stayed low in prevalence (under 1% in U.S. surveillance) and did not drive surges or policy changes. Vaccine updates for the 2025–26 and 2026–27 seasons target dominant circulating strains like XFG lineages, supporting expectations of continued incremental Omicron evolution rather than a disruptive new designation. With roughly 17 months until 2027, the market pricing aligns with the pattern of stable, low-consequence variant activity and robust monitoring systems.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問